ArticleAnnals of medicine and surgery (2012)2026
Targeting neuroinflammation to enhance recovery after brain injury.
Article in Annals of medicine and surgery (2012), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Traumatic brain injury (TBI) continues to be a major global cause of morbidity and mortality, with neuroinflammation recognized as a central mechanism influencing both acute and long-term outcomes. Following the initial insult, activation of glial cells, cytokine release, and blood-brain barrier disruption drive a cascade of secondary injury. While these inflammatory processes contribute to debris clearance and neurorepair, excessive or prolonged activation leads to neuronal death and chronic neurodegeneration. Recent international research has focused on modulating these pathways to enhance recovery. In the United States and Germany, trials using stem cell derived exosomes and anti-cytokine biologics have shown neuroprotective potential. In China, novel compounds such as 3-monothiopomalidomide have demonstrated efficacy in reducing microglial activation and improving behavioral outcomes in experimental TBI. Integrating these pharmacological, cellular, and imaging innovations into clinical care could transform TBI management. This letter underscores the need for global collaboration, transparent data use, and biomarker-driven neuroinflammatory modulation to optimize adult brain injury recovery.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.